Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India, says GlobalData
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Ayurveda is one of the most advanced sciences of its times
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Subscribe To Our Newsletter & Stay Updated